Medarex News

Bristol-Myers Squibb is making progress developing a new drug to assist the body's immune system in its ability to find and attack cancer cells.

It would be a triumphant moment for any governor: A cutting-edge company announces plans to build a new plant that will create hundreds of high-paying jobs and bolster one of the state's most prominent industries.

In addition to Bristol-Myers Squibb, the II-ON is currently comprised of ten leading cancer-research institutions, including: "The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes." .Clinica Universidad Navarra, Pamplona, ... (more)

Bristol-Myers Squibb has formed the International Immuno-Oncology Network , a global collaboration between industry and academia intended to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the body's immune system to fight cancer.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

Lamberto Andreotti , chief executive officer, will answer questions about the company at 9 a.m. EST.

Editor's Note: The following is a news release issued by the Mercer County chapter of the National Alliance on Mental Illness.

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.

Shares of Bristol Myers Squibb opened at 32.75 on Friday. Bristol Myers Squibb has a 52 week low of $25.69 and a 52 week high of $35.44. The company has a market cap of $55.318 billion and a P/E ratio of 14.69. Bristol Myers Squibb last announced its earnings results on Thursday, April 26th.

Two items on Thursday from Human Genome Sciences , as it reports that adoption of a rights plan for short-term shareholders, which will have the term of one year.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia May 16, 2012 -- Announcing two separate strategic China initiatives yesterday, Bristol-Myers Squibb increased its commitment to building its presence in China and its bid for ... (more)

Editor's Note: The following advisory was issued today by the Lawrence Township Health Department.

Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.'s Plavix after the drug loses U.S. patent protection Thursday.

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J. -- -- Bristol-Myers Squibb Company today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the ... (more)

Methods Patients who initiated warfarin therapy between Jan 2005 and Jun 2009 and had a healthcare claim related to AF within 30 days prior to the first warfarin claim, but no evidence of valvular disease, were included.

NEW YORK Football fans going to the games this fall can get a program, a foam finger, and a cancer screening.

Bristol-Myers Squibb Company and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership.

Bristol-Myers Squibb Company to Present New Data on ORENCIA at the European League Against Rheumatism 2012 Congress Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company today announced that the company ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia - ISPE continued its mission to provide a neutral ground for pharmaceutical industry professionals and regulators to discuss industry issues at ISPE Affiliate meetings in Japan ... (more)